| Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Meniere's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Karam Sammy | SENIOR VICE PRESIDENT | Dec 29 | Sale | 108.75 | 4,200 | 456,750 | 26,462 | Jan 03 05:32 PM | | Ginascol John F | EXECUTIVE VICE PRESIDENT | Dec 13 | Sale | 112.32 | 11,000 | 1,235,520 | 111,912 | Dec 15 05:26 PM | | STARKS DANIEL J | Director | Oct 27 | Sale | 97.46 | 50,000 | 4,872,932 | 6,873,500 | Oct 31 05:44 PM | | MANNING JOSEPH J | EXECUTIVE VICE PRESIDENT | Sep 08 | Option Exercise | 44.40 | 23,008 | 1,021,555 | 76,253 | Sep 09 05:27 PM | | MANNING JOSEPH J | EXECUTIVE VICE PRESIDENT | Sep 08 | Sale | 107.00 | 23,008 | 2,461,856 | 53,245 | Sep 09 05:27 PM | | MANNING JOSEPH J | EXECUTIVE VICE PRESIDENT | Aug 25 | Option Exercise | 44.40 | 23,008 | 1,021,555 | 80,143 | Aug 26 05:46 PM | | Ford Robert B | CHAIRMAN AND CEO | Aug 25 | Option Exercise | 40.24 | 102,425 | 4,121,871 | 244,496 | Aug 26 05:49 PM | | Ford Robert B | CHAIRMAN AND CEO | Aug 25 | Sale | 105.10 | 102,425 | 10,765,154 | 142,071 | Aug 26 05:49 PM | | MANNING JOSEPH J | EXECUTIVE VICE PRESIDENT | Aug 25 | Sale | 105.03 | 26,898 | 2,825,088 | 53,245 | Aug 26 05:46 PM | | STARKS DANIEL J | Director | Jul 26 | Sale | 109.14 | 50,000 | 5,456,994 | 6,923,500 | Jul 28 05:20 PM | | Mateus Fernando | SENIOR VICE PRESIDENT | Jul 26 | Sale | 109.05 | 2,457 | 267,943 | 14,503 | Jul 27 05:45 PM | | Tyler Julie L. | SENIOR VICE PRESIDENT | Jul 25 | Sale | 109.09 | 253 | 27,600 | 33,868 | Jul 27 05:43 PM | | WOODGRIFT RANDEL WILLIAM | SENIOR VICE PRESIDENT | May 04 | Option Exercise | 44.40 | 24,000 | 1,065,600 | 71,854 | May 05 06:12 PM | | WOODGRIFT RANDEL WILLIAM | SENIOR VICE PRESIDENT | May 04 | Sale | 113.00 | 24,000 | 2,712,103 | 47,854 | May 05 06:12 PM | | STARKS DANIEL J | Director | May 03 | Sale | 113.22 | 50,000 | 5,661,048 | 6,973,500 | May 05 05:15 PM | | DALE MICHAEL D | SENIOR VICE PRESIDENT | Mar 08 | Sale | 117.00 | 4,000 | 468,001 | 41,780 | Mar 10 05:25 PM | | WOODGRIFT RANDEL WILLIAM | SENIOR VICE PRESIDENT | Mar 01 | Sale | 118.10 | 964 | 113,849 | 49,223 | Mar 02 08:07 PM | | Watkin Jared | SENIOR VICE PRESIDENT | Mar 01 | Sale | 118.10 | 1,038 | 122,589 | 66,545 | Mar 02 08:02 PM | | Wainer Andrea F | EXECUTIVE VICE PRESIDENT | Mar 01 | Sale | 118.13 | 456 | 53,866 | 62,172 | Mar 02 08:00 PM | | Salvadori Daniel Gesua Sive | EXECUTIVE VICE PRESIDENT | Mar 01 | Sale | 118.17 | 1,550 | 183,165 | 112,248 | Mar 02 07:58 PM | | Morrone Louis H. | SENIOR VICE PRESIDENT | Mar 01 | Sale | 118.16 | 656 | 77,513 | 47,278 | Mar 02 07:54 PM | | MANNING JOSEPH J | EXECUTIVE VICE PRESIDENT | Mar 01 | Sale | 118.16 | 779 | 92,047 | 60,873 | Mar 02 07:51 PM | | Earnhardt Lisa D | EXECUTIVE VICE PRESIDENT | Mar 01 | Sale | 118.15 | 943 | 111,416 | 90,630 | Mar 02 07:38 PM | | DALE MICHAEL D | SENIOR VICE PRESIDENT | Mar 01 | Sale | 118.15 | 1,053 | 124,412 | 45,780 | Mar 02 07:36 PM | | Calamari Christopher J. | SENIOR VICE PRESIDENT | Mar 01 | Sale | 118.15 | 706 | 83,414 | 25,658 | Mar 02 07:33 PM | | ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT | Mar 01 | Sale | 118.17 | 1,450 | 171,348 | 167,095 | Mar 02 07:29 PM | | Ahlberg Gregory A | SENIOR VICE PRESIDENT | Mar 01 | Sale | 118.15 | 1,099 | 129,847 | 33,274 | Mar 02 07:27 PM | | McKinstry Nancy | Director | Feb 24 | Option Exercise | 29.84 | 6,280 | 187,394 | 33,419 | Feb 25 05:23 PM | | McKinstry Nancy | Director | Feb 24 | Sale | 116.42 | 1,614 | 187,910 | 31,805 | Feb 25 05:23 PM | | Tyler Julie L. | SENIOR VICE PRESIDENT | Feb 22 | Sale | 119.29 | 462 | 55,114 | 34,703 | Feb 23 08:31 PM |
|
